All In Biotech

BLA 021172 · Novo Nordisk INC

Novolog Mix 70/30 Penfill

Insulin Aspart Protamine Recombinant, Insulin Aspart Recombinant · Subcutaneous · Insulin Analog

Priority review

Last checked: Nov 20, 2026Latest source record: Feb 28, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

Nov 1, 2001

Approved uses

4

Original approval plus efficacy supplements

Registered trials

99

28 Phase 3, 0 recruiting

FAERS reports

12,980

10,763 serious, 1,506 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 18, 2026.

NOVOLOG MIX 70/30 is a mixture of insulin aspart protamine and insulin aspart indicated to improve glycemic control in adult patients with diabetes mellitus. Limitations of Use: NOVOLOG MIX 70/30 is not recommended for the treatment of diabetic ketoacidosis. The proportions of rapid-acting and long-acting insulins in NOVOLOG MIX 70/30 are fixed and do not allow for basal versus prandial dose adjustments. NOVOLOG MIX 70/30 is a mixture of insulin aspart protamine, an intermediate-acting human insulin analog, and insulin aspart, a rapid-acting human insulin analog, indicated to improve glycemic control in adult patients with diabetes mellitus. Limitations of Use: Not recommended for the treatment of diabetic ketoacidosis. The proportions of rapid-acting and long-acting insulins are fixed and do not allow for basal versus prandial dose adjustments (1) .

Mechanism: The primary activity of insulin, including NOVOLOG MIX 70/30 is the regulation of glucose metabolism. Insulin and its analog lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • NOVOLOG MIX 70/30 PENFILL · INSULIN ASPART PROTAMINE RECOMBINANT 210 UNITS/3ML; INSULIN ASPART RECOMBINANT 90 UNITS/3ML (70 UNITS/ML · INJECTABLE, SUBCUTANEOUS · Discontinued
  • NOVOLOG MIX 70/30 · INSULIN ASPART PROTAMINE RECOMBINANT 700 UNITS/10ML; INSULIN ASPART RECOMBINANT 300 UNITS/10ML (70 UNITS/ML · INJECTABLE, SUBCUTANEOUS · Prescription
  • NOVOLOG MIX 70/30 FLEXPEN · INSULIN ASPART PROTAMINE RECOMBINANT 210 UNITS/3ML; INSULIN ASPART RECOMBINANT 90 UNITS/3ML (70 UNITS/ML · INJECTABLE, SUBCUTANEOUS · Prescription
  • NOVOLOG MIX 70/30 PENFILL · INSULIN ASPART PROTAMINE RECOMBINANT 210 UNITS/3ML; INSULIN ASPART RECOMBINANT 90 UNITS/3ML (70 UNITS/ML · INJECTABLE, SUBCUTANEOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Insulin Aspart Protamine Recombinant" as an intervention, any sponsor and status, largest first.

All 99 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased1,265
  • nausea839
  • dyspnoea793
  • hypoglycaemia737
  • vomiting698
  • off label use645
  • drug ineffective532
  • diarrhoea522
  • condition aggravated504
  • abdominal pain500
  • fatigue486
  • dizziness451

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200465
200595
2006155
2007243
2008313
2009308
2010215
2011236
2012280
2013225
2014277
2015515
2016526
2017573
2018670
2019622
2020790
20211,050
20221,158
20231,047
20241,159
20251,440
20261,018

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Novolog Mix 70-30 (Insulin Aspart Prot/Insuln Asp)

2024 spending

$11.4M

Beneficiaries

12,616

49,697 claims

Per beneficiary

$905

$6.92 per unit

View as table
YearSpending
2020$112,025,124
2021$91,396,260
2022$77,996,678
2023$66,766,546
2024$11,420,216

Part D: Novolog Mix 70-30 Flexpen (Insulin Aspart Prot/Insuln Asp)

2024 spending

$66.9M

Beneficiaries

58,653

241,710 claims

Per beneficiary

$1,140

$8.81 per unit

View as table
YearSpending
2020$421,364,939
2021$386,853,952
2022$357,828,485
2023$335,124,166
2024$66,851,234

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Novo Nordisk · Also marketed as Novolog Mix 70/30, Novolog Mix 70/30 Flexpen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.